Audit: QRS - Microdosing Mescaline for Health & Longevity

Audit conducted on 22/09/2026 19:11 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked against ER: dose 10–15 mg (ER 415, 438), 1-day-on/2-off (ER 444), morning before 10:00 (ER 446), 3.5 h half-life and >95% at 18 h (ER 448), all 10 biomarkers and cadence (ER 523–534).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Claimed cumulative benefit”, “Blinded trials at this horizon found no separation from placebo”, “Reported gains may be expectation”, “entirely speculative” mirror ER hedging (ER 495, 529, 571).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, study citations, expert names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the QRS.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢	No second-person pronouns anywhere in the QRS.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“Administered orally” used in action_3_sub (line 487) rather than “taken by mouth”; at-a-glance wording mirrors the ER Conclusion voice (ER 569).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and table headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present; repeating rows expanded to marker_1–marker_10 and qualitative_item_1–qualitative_item_6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against QRS.html shows all non-variable markup, CSS and the website=”…” spans unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relevant to the QRS is empty; no empty-state phrasing is required.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Monitoring row labels use the ER biomarker names verbatim; “Best time of day” (line 480) is the ER bold label verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters present; the ER tier emojis were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is reduced to phrase-level entries with no elaborations, citations or effect sizes.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Microdosing Mescaline for Health & Longevity - Quick Reference Sheet” (line 22), “&” correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	qrs_creation_date 2026-0922-1817 → 09/22/2026 (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	67 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 11 avoidance bullets (ER 396–406) plus the two absolute contraindications, MAOIs and lithium (ER 374, 376), are present as 12 items.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds preserved: systolic ≥160 / diastolic ≥100 mmHg, MI within 90 days, eGFR <45, Child-Pugh C, NYHA III/IV.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty (12 contraindication items present).

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine interaction items; MAOIs, lithium and Peganum harmala correctly excluded (they sit under Contraindications).
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved for every item, trimmed to fit the one-page budget as 9.5 permits.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty (9 interaction items present).

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable aspects exist in the ER; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Acute effects and effect duration map to the High-tier pharmacology benefit; cumulative benefit maps to the Medium-tier mood benefit.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist in the ER; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER 495, 446, 448); the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items in the ER; no tier span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers have items in the ER; no tier span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 10 biomarkers from the ER table (ER 523–532) are present, in ER order.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 6 qualitative markers from ER 538–543 are present, in ER order.

Issues 22/09/2026 19:11

Pass rate 100.00%. No issues found.

Issues 22/09/2026 19:03

1. 1.3 — Hypertension gate threshold softened: Line 585 renders the uncontrolled-hypertension contraindication as “(seated ≥ 160/100 mmHg)”, but the ER (line 397) defines it as “seated systolic ≥ 160 mmHg or diastolic ≥ 100 mmHg”; the slash form implies both readings must be met and so narrows an absolute gate.
2. 1.1 — Antidepressant class renamed: Line 602 lists “Serotonin and serotonin-noradrenaline reuptake inhibitors”, dropping “Selective” from the ER’s “Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors” (ER line 378) and widening the named class beyond what the ER states.

Fixes 22/09/2026 19:03

1. 1.3 — Hypertension gate threshold restored: Changed the contraindication from “Uncontrolled hypertension (seated ≥ 160/100 mmHg)” to “Uncontrolled hypertension (seated systolic ≥ 160 or diastolic ≥ 100 mmHg)”, restoring the ER’s either/or threshold.
2. 1.1 — Antidepressant class name restored: Changed the interaction item from “Serotonin and serotonin-noradrenaline reuptake inhibitors” to “Selective serotonin and serotonin-noradrenaline reuptake inhibitors”, matching the ER’s class naming.

Issues 22/09/2026 18:54

1. 4.5 — Sheet exceeds one A4 page: The populated sheet runs to roughly two A4 pages — 12 contraindications and 9 key-interaction items (lines 580-637), a 10-row monitoring table (lines 688-835), six protocol sub-cells of 4-5 lines each (lines 456-539) and a three-line cadence paragraph (lines 840-844) — with no per-section condensation applied.

Fixes 22/09/2026 18:54

1. 4.5 — Protocol sub-cells condensed: Trimmed all six protocol and time-to-effect sub-cells, removing restatements that duplicated the cell value (e.g. time_1_sub from “Onset at roughly 1 hour, peak at 2 hours after an oral dose; the within-day effect is unambiguous.” to “Onset at roughly 1 hour, peak at 2 hours after an oral dose.”), cutting the panel by roughly a third.
2. 4.5 — Gate parenthetical lists shortened: Reduced the longest example-drug lists in the Contraindications and Key Interactions gates to representative exemplars (antihypertensives from six drugs to three; antipsychotics from seven to five; reuptake inhibitors from seven to five), preserving every class and never dropping a parenthetical entirely.
3. 4.5 — Monitoring “Why” column tightened: Shortened seven of the ten marker rationales so each fits a single line (e.g. marker_4_why from “Roughly half of a dose is cleared unchanged renally, so filtration sets exposure” to “Roughly half of a dose is cleared renally, so filtration sets exposure”), and condensed the cadence line, without removing any of the ten biomarkers.

Issues 22/09/2026 18:47

1. 4.2 / 4.3 — Protocol label not verbatim: action_3_label at QRS line 481 reads “Time of day”, but the ER bullet it maps one-to-one to is “Best time of day:” (ER line 446); the label is abbreviated rather than carried verbatim.

Fixes 22/09/2026 18:47

1. 4.2 / 4.3 — Protocol label not verbatim: Changed action_3_label from “Time of day” to the ER’s verbatim bold label “Best time of day” (ER line 446).

Issues 22/09/2026 18:42

1. 1.1 — Monitoring “why” garbled by condensation: QRS line 695-697 states “Detects the documented blood-pressure rise before dosing”; the ER (line 523) reads “Detects the documented blood-pressure rise and defines the safety margin before dosing”, so the QRS asserts a rise can be detected before dosing, which the ER does not support.
2. 1.3 — Titration bounds turned into fixed values: QRS lines 457-460 state “held three dosing occasions before any 5 mg increment”, while ER line 415 says “held for at least three dosing occasions before any increase, with increments of no more than 5 mg”.
3. 4.3 — SSRI class label abbreviated: QRS lines 604-607 render the ER’s bold label “Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors” (ER line 378) as “Serotonin and serotonin-noradrenaline reuptake inhibitors”, dropping “Selective” and thereby renaming the drug class.

Fixes 22/09/2026 18:42

1. 1.1 — Monitoring “why” restored: Changed marker_1_why from “Detects the documented blood-pressure rise before dosing” to “Detects the documented blood-pressure rise and defines the safety margin”, matching the ER wording.
2. 1.3 — Titration bounds restored: Changed action_1_sub from “held three dosing occasions before any 5 mg increment” to “held at least three dosing occasions before any increase, in increments of no more than 5 mg”.
3. 4.3 — SSRI class label restored: Changed the first caution item label from “Serotonin and serotonin-noradrenaline reuptake inhibitors” to the ER’s “Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors”.

Issues 22/09/2026 18:35

1. 4.5 — Sheet overruns one A4 page: The QRS does not fit a single A4 page; the decision-gate block (lines 576–640) and the 10-row Monitoring table with its cadence paragraph (lines 679–849) each consume close to half a page on their own, and the protocol sub-lines (lines 457–460, 472–475) run to six and seven wrapped lines where the cell budget allows roughly four.

Fixes 22/09/2026 18:35

1. 4.5 — Protocol sub-lines condensed: Shortened all three action_#_sub cells (from 208, 231 and 132 characters to 149, 162 and 136), cutting the deepest protocol cell from seven wrapped lines to four.
2. 4.5 — Time-to-effect sub-lines condensed: Trimmed all three time_#_sub cells (“immediate and unambiguous” to “unambiguous”, “is cleared” to “clears”, “Reported to emerge over repeated dosing” to “Reported over repeated dosing”), dropping the row from four lines to three.
3. 4.5 — Key Interactions items trimmed: Removed filler from three caution_items (“triptans such as sumatriptan” to “sumatriptan”, Hypericum perforatum to “St. John’s wort”, “Deliberate heat exposure” to “Heat exposure”), cutting three wrapped lines without dropping any named drug or exposure.
4. 4.5 — Monitoring “Why” cells condensed: Shortened six marker_#_why cells, bringing the blood-pressure, heart-rate and glycated-haemoglobin rows down to a single line each.
5. 4.5 — Cadence and qualitative item condensed: Reduced monitoring_cadence from 305 to 234 characters (three lines to two) and qualitative_item_6 from 143 to 92 characters (two lines to one), retaining the perceptual-anomaly examples and the stop-signal framing.

Issues 22/09/2026 18:24

1. 2.8 / 4.5 — Content not condensed for one page: The Monitoring “why” cells (lines 706–848), [monitoring_cadence] (lines 854–860) and the six [qualitative_item_*] spans (lines 869–898) reproduce full ER sentences with their trailing rationale clauses verbatim, and [action_1_sub] runs to 45 words; the estimated rendered height is roughly 2.4 A4 pages against a one-page budget.
2. 1.3 — Fadiman schedule presented as default: [action_2_sub] (lines 473–477) opens “The Fadiman schedule; …” as though it were the protocol, whereas ER line 444 states “Neither Fadiman’s protocol nor Stamets’s is presented here as the default; the every-48-hour minimum is the point of agreement between them.”

Fixes 22/09/2026 18:24

1. 1.3 — Fadiman schedule no longer the default: Rewrote [action_2_sub] from “The Fadiman schedule; a minimum 48-hour interval … is the point of agreement across described protocols” to “The most widely used schedule, though no schedule is presented as a default; the minimum 48-hour interval, never daily, is the point of agreement across described protocols”, matching the ER’s explicit refusal to name a default.
2. 2.8 / 4.5 — Monitoring rationales condensed: Shortened all ten [marker_#_why] cells from verbatim ER sentences to compact reasons (e.g. marker_3 from “Screens for pre-existing conduction abnormality that would amplify the consequence of the cardiovascular effect” to “Screens for conduction abnormality that would amplify the cardiovascular effect”).
3. 2.8 / 4.5 — Monitoring cadence tightened: Condensed [monitoring_cadence] from the 60-word verbatim ER sentence to a compact form, keeping every interval (first four doses, weekly, 3 months, 6–12 months, beyond 12 months, 12–24 months).
4. 2.8 / 4.5 — Qualitative items compacted: Stripped the trailing rationale clauses from [qualitative_item_1], [qualitative_item_3] and [qualitative_item_4] and tightened the wording, leaving all six markers present.
5. 2.8 / 4.5 — Protocol and time-to-effect subs shortened: Condensed all three [action_#sub] and all three [time#_sub] spans, preserving every dose, threshold and interval ([action_1_sub] cut from 45 to 33 words).
6. 2.8 / 4.5 — Decision-gate items tightened: Reworded the twelve [stop_items] and nine [caution_items] into shorter form (e.g. “seated systolic ≥ 160 mmHg or diastolic ≥ 100 mmHg” to “seated ≥ 160/100 mmHg”), keeping every threshold, staging class, time window and named drug.